Charles Schwab Investment Management Inc C4 Therapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

$557 Billion
Q2 2025

A detailed history of Charles Schwab Investment Management Inc transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 331,897 shares of CCCC stock, worth $816,466. This represents 0.0% of its overall portfolio holdings.

Number of Shares

331,897

Previous 474,843 30.1%

Holding current value

$816,466

Previous $759,000 37.55%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	SELL	$1.1 - $1.74 $157,240 - $248,726	-142,946 Reduced 30.1%	331,897 $474,000
Q1 2025 Sep 15, 2025	BUY	$1.6 - $4.09 $228,713 - $584,649	142,946 Added 43.07%	474,843 $759,000
Q1 2025 May 09, 2025	SELL	$1.6 - $4.09 $18,436 - $47,129	-11,523 Reduced 2.37%	474,843 $759,000
Q4 2024 Feb 06, 2025	BUY	$3.6 - $7.0 $12,373 - $24,059	3,437 Added 0.71%	486,366 $1.75 Million
Q3 2024 Nov 12, 2024	SELL	$4.43 - $7.38 $26,708 - $44,494	-6,029 Reduced 1.23%	482,929 $2.75 Million
Q2 2024 Aug 12, 2024	BUY	$4.05 - $8.1 $897,192 - $1.79 Million	221,529 Added 82.84%	488,958 $2.26 Million
Q1 2024 May 08, 2024	BUY	$5.3 - $11.0 $78,010 - $161,909	14,719 Added 5.82%	267,429 $2.18 Million
Q4 2023 Feb 06, 2024	BUY	$1.18 - $6.03 $5,260 - $26,881	4,458 Added 1.8%	252,710 $1.43 Million
Q3 2023 Nov 08, 2023	BUY	$1.81 - $3.89 $31,164 - $66,978	17,218 Added 7.45%	248,252 $461,000
Q2 2023 Aug 09, 2023	SELL	$2.75 - $3.77 $236,431 - $324,125	-85,975 Reduced 27.12%	231,034 $635,000
Q1 2023 May 11, 2023	SELL	$3.1 - $9.02 $122,893 - $357,579	-39,643 Reduced 11.12%	317,009 $995,000
Q4 2022 Feb 13, 2023	BUY	$5.42 - $10.24 $24,536 - $46,356	4,527 Added 1.29%	356,652 $2.1 Million
Q3 2022 Nov 14, 2022	BUY	$8.03 - $12.77 $633,856 - $1.01 Million	78,936 Added 28.89%	352,125 $3.09 Million
Q2 2022 Aug 15, 2022	BUY	$5.06 - $26.46 $263 - $1,375	52 Added 0.02%	273,189 $2.06 Million
Q1 2022 May 13, 2022	BUY	$19.99 - $33.23 $169,635 - $281,989	8,486 Added 3.21%	273,137 $6.63 Million
Q4 2021 Feb 11, 2022	BUY	$29.39 - $46.86 $123,408 - $196,765	4,199 Added 1.61%	264,651 $8.52 Million
Q3 2021 Nov 16, 2021	BUY	$35.91 - $50.5 $4.3 Million - $6.05 Million	119,858 Added 85.25%	260,452 $11.6 Million
Q2 2021 Aug 16, 2021	BUY	$30.39 - $42.18 $2.15 Million - $2.99 Million	70,882 Added 101.68%	140,594 $5.32 Million
Q1 2021 May 17, 2021	BUY	$31.96 - $46.5 $94,921 - $138,105	2,970 Added 4.45%	69,712 $2.58 Million
Q4 2020 Feb 16, 2021	BUY	$22.8 - $37.05 $1.52 Million - $2.47 Million	66,742 New	66,742 $2.21 Million

Others Institutions Holding CCCC

# of Institutions

102

Shares Held

57.2M

Call Options Held

15.2K

Put Options Held

View Full List

About C4 Therapeutics, Inc.

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $120M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

More about CCCC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc C4 Therapeutics, Inc. Transaction History